News › Clinical Practice, Industry News, Patient Care

FDA Approves First GLP-1 Generic for Weight Loss

August 29, 2025

The U.S. Food and Drug Administration (FDA) has approved Teva Pharmaceuticals’ generic version of Novo Nordisk’s Saxenda (liraglutide), a first-generation glucagon-like peptide-1 (GLP-1) receptor agonist. The generic is approved to treat adults and adolescents 12 to 17 years of age who are obese or overweight. This is the first time a generic glucagon-like peptide-1 receptor agonist (GLP-1RA) medication has been approved for weight loss in the US.

Read more at Reuters >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Growth, Capital and Control: Navigating Private Equity in Aesthetics
    • Med Spas Under the Microscope – The View From The FDA
    • Revance and Teoxane Announce RHA Dynamic Volume is Now Available
    • Terri Ross Consulting Appoints Cameron Hemphill as Chief Operating Officer and Strategic Advisor
    • Galderma’s Restylane Contour Gains FDA Approval for the Correction of Temple Hollowing